Coherus Oncology Inc (CHRS)

EBITDA

-$148.46M

TTM · Period ending: · USD

CHRS logo

CHRS EBITDA

Latest reported-$148.46M
CHRS EBITDA (-$31.28M → -$148.46M)
High-resolution chart · PNG

CHRS ebitda history

Annual fiscal periods · USD. Dates are reporting period ends; fiscal years can differ from calendar years.

Coherus Oncology Inc EBITDA — Annual fiscal periods (USD)
Period endingEBITDA (USD)
-170,199,000
60,941,000
-193,939,000
-255,581,000
-260,687,000
159,761,000
111,027,000
-204,416,000
-225,336,000
-116,812,000
-222,036,000
-82,715,000
-47,938,000
-31,283,000
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.